CALA CALA

Calithera Biosciences Stock Price

FREE CALA REPORT

0.42
-0.01 (-2.33%)
0.42
Volume 255,043
Bid Price 0.4008
Ask Price 0.42
News -
Day High 0.439

Low
0.139

52 Week Range

High
5.10

Day Low 0.4005
Company Name Stock Ticker Symbol Market Type
Calithera Biosciences Inc CALA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -2.33% 0.42 16:05:02
Open Price Low Price High Price Close Price Prev Close
0.43 0.4005 0.439 0.416 0.43
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
464 255,043 $ 0.413703 $ 105,512 - 0.139 - 5.10
Last Trade Time Type Quantity Stock Price Currency
16:05:02 formt 250 $ 0.42 USD

Period:

Draw Mode:

Calithera Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.04M 4.87M 4.68M $ 9.75M $ - -31.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 24.90%

more financials information »

Calithera Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CALA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.48680.4999990.400.4437257352,577-0.0668-13.72%
1 Month2.973.68380.400.6643756696,269-2.55-85.86%
3 Months2.483.68380.400.9078133255,588-2.06-83.06%
6 Months3.145.100.401.64160,735-2.72-86.62%
1 Year0.44335.100.1390.45923591,232,734-0.0233-5.26%
3 Years6.558.180.1392.001,067,560-6.13-93.59%
5 Years8.459.350.1392.63797,830-8.03-95.03%

Calithera Biosciences Description

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.